1. CHECKMATE 647: A PHASE 2, OPEN‐LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA. (June 2017) Authors: Nayak, L.; Iwamoto, F.M.; Ferreri, A.J.; Santoro, A.; Singer, S.; Batlevi, C.; Batchelor, T.; Rubenstein, J.; Johnston, P.; Ramchandren, R.; Soussain, C.; Drappatz, J.; Becker, K.; Witzens‐Harig, M.; Illerhaus, G.; Herrera, A.; Masood, A.; Shipp, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 420 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL. (June 2017) Authors: Fanale, M.; Engert, A.; Younes, A.; Armand, P.; Ansell, S.; Zinzani, P.L.; Timmerman, J.M.; Collins, G.P.; Ramchandren, R.; Cohen, J.B.; De Boer, J.P.; Kuruvilla, J.; Savage, K.J.; Trneny, M.; Rodig, S.; Shipp, M.; Kato, K.; Sumbul, A.; Farsaci, B.; Santoro, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗